Pasithea's Trading Volume Surges 3028.32% to 634 Million, Climbs to 111th in Daily Rankings

On May 6, 2025, Pasithea's trading volume reached 634 million, marking a significant increase of 3028.32% compared to the previous day. This surge placed Pasithea at the 111th position in the daily stock market rankings. Pasithea (KTTA) has been on a rising trend, increasing by 7.04% and maintaining a 2-day consecutive rise, with a total increase of 8.57% over the past two days.

Pasithea Therapeutics, a company focused on developing psychedelic medicines, has recently announced a strategic partnership with a leading research institution. This collaboration aims to accelerate the development of innovative treatments for mental health disorders, leveraging the institution's expertise in neuroscience and Pasithea's proprietary technology.

In addition to the partnership, Pasithea has also received approval from regulatory authorities to commence Phase II clinical trials for its flagship product, a novel psychedelic compound designed to treat depression. This milestone marks a significant step forward in the company's mission to revolutionize mental health treatment.

Furthermore, Pasithea has expanded its executive team by appointing a new Chief Scientific Officer, who brings extensive experience in pharmaceutical research and development. This addition is expected to strengthen the company's scientific capabilities and drive forward its pipeline of psychedelic therapies.